ArticleJournal of gastroenterology and hepatology2025
Differences in Clinical Characteristics Between Missed and Detected Laryngopharyngeal Cancers.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Differences in Clinical Characteristics Between Missed and Detected Laryngopharyngeal Cancers.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimLaryngopharyngeal cancers are often overlooked during endoscopy because of their anatomical complexity and the gag reflex. However, the characteristics of these cancers remain poorly understood. We studied the differences in clinical characteristics and endoscopic procedures between missed and detected cancers.
methodsNewly diagnosed laryngopharyngeal squamous cell carcinomas identified during esophagogastroduodenoscopy at our hospital between January 2016 and December 2020 were analyzed. A total of 179 lesions were categorized into two groups: missed (n = 74) and detected (n = 105). Missed cancer was defined as a lesion identified within 18 months of preceding esophagogastroduodenoscopy at our hospital, while detected cancer was defined as a lesion not included in the missed group.
resultsThe miss rate of laryngopharyngeal cancers on esophagogastroduodenoscopy was 41.3%. Multivariate analysis showed that the non-use rate of pethidine hydrochloride (odds ratio 4.1, 95% confidence interval 2.0-8.6, p < 0.01), ratio of white-light imaging ≥ narrow-band imaging through observation of laryngopharynx (odds ratio 31.8, 95% confidence interval 3.9-258.0, p < 0.01), and number of "comprehensiveness of laryngopharyngeal observation" negatives (odds ratio 2.6, 95% confidence interval 1.3-5.4, p = 0.01) were significantly larger in the missed group. Univariate analysis showed that the number of tumors located on the epiglottis (p = 0.02) was significantly larger in the missed group.
conclusionsThis study highlights the importance of precisely observing the laryngopharynx, facilitated by the use of pethidine hydrochloride and narrow-band imaging. In addition, epiglottic lesions are frequently missed. Comprehensive observation of the laryngopharynx using narrow-band imaging and premedication may reduce the frequency of missed cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.